The PTAB has instituted IPR2016-01837, in which Hospira challenges Genentech’s U.S. Patent 7,807,799. The institution decision extends to all challenged claims, claims 1-3 and 5-11. According to the decision, the ‘799 patent relates to improved methods for conducting protein A affinity chromatography, and the specification includes an example using trastuzumab. Trastuzumab is marketed by Genentech under the trade-name Herceptin®, and is indicated for treating certain types of breast cancer.
This decision and other important documents related to IPRs on biologic patents are posted to our IPR tracker page.
The post PTAB Institutes IPR in Hospira’s Challenge to Genentech’s Trastuzumab Patent appeared first on Goodwin Procter BioSimilars Blog.